-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 31, Puli Pharmaceuticals issued an announcement stating that the company had recently received a marketing permit for 200 mg of voriconazole for injection issued by the Ministry of Health of Costa Rica
Voriconazole is a broad-spectrum triazole antifungal agent that treats invasive aspergillosis, candidaemia in patients with non-neutropenia, and severe invasive infections caused by fluconazole-resistant Candida ( Including Candida krusei), a serious infection caused by Actinomyces spp.
Voriconazole for injection was developed by Pfizer.